PMID- 33718461
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210316
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 8
DP  - 2021
TI  - Type 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and 
      Perspective.
PG  - 644189
LID - 10.3389/fcvm.2021.644189 [doi]
LID - 644189
AB  - Type 2 diabetes mellitus (T2DM) and its complications are seriously affecting 
      public health worldwide. Myocardial infarction (MI) is the primary cause of death 
      in patients with T2DM. T2DM patients without a history of coronary artery disease 
      (CAD) have the same risk of major coronary events as those with CAD; T2DM 
      patients with a history of MI have >40% risk of recurrence of MI. Thus, CAD in 
      patients with T2DM needs to be treated actively to reduce the risk of MI. The 
      cardiology community focused on the role of T2DM in the development of CAD and on 
      the related issues of T2DM and MI with respect to comorbidities, prognosis, drug 
      therapy, and heredity. In this mini review, the latest progress of clinical 
      evidence-based research between T2DM and MI in recent years was reviewed, and the 
      possible research directions in this field were considered and prospected.
CI  - Copyright (c) 2021 Cui, Liu, Li, Xu and Liu.
FAU - Cui, Jing
AU  - Cui J
AD  - Cardiovascular Centre of Xiyuan Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
AD  - National Clinical Research Centre for Chinese Medicine Cardiology, Beijing, 
      China.
FAU - Liu, Yanfei
AU  - Liu Y
AD  - Institute of Clinical Pharmacology, Xiyuan Hospital of China Academy of Chinese 
      Medical Sciences, Beijing, China.
FAU - Li, Yiwen
AU  - Li Y
AD  - Cardiovascular Centre of Xiyuan Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
AD  - National Clinical Research Centre for Chinese Medicine Cardiology, Beijing, 
      China.
AD  - China Center for Evidence-Based Medicine of Chinese Medicine, Beijing, China.
FAU - Xu, Fengqin
AU  - Xu F
AD  - National Clinical Research Centre for Chinese Medicine Cardiology, Beijing, 
      China.
AD  - China Center for Evidence-Based Medicine of Chinese Medicine, Beijing, China.
FAU - Liu, Yue
AU  - Liu Y
AD  - Cardiovascular Centre of Xiyuan Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, China.
AD  - National Clinical Research Centre for Chinese Medicine Cardiology, Beijing, 
      China.
AD  - China Center for Evidence-Based Medicine of Chinese Medicine, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210224
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC7943438
OTO - NOTNLM
OT  - drug
OT  - evidence-based medicine
OT  - myocardial infarction
OT  - sodium-glucose cotransporter-2 inhibitor
OT  - type 2 diabetes
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/03/16 06:00
MHDA- 2021/03/16 06:01
PMCR- 2021/01/01
CRDT- 2021/03/15 07:09
PHST- 2020/12/20 00:00 [received]
PHST- 2021/01/19 00:00 [accepted]
PHST- 2021/03/15 07:09 [entrez]
PHST- 2021/03/16 06:00 [pubmed]
PHST- 2021/03/16 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2021.644189 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2021 Feb 24;8:644189. doi: 10.3389/fcvm.2021.644189. 
      eCollection 2021.